Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologySierra Health and Life Tezspire Coverage Update | …
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0110K

    Tezspire (tezepelumab-ekko) — provider-administered therapy

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0110K alerts

    Get alerted when Policy 2026D0110K changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers clinical medical benefit criteria for provider-administered Tezspire (tezepelumab-ekko) as add-on maintenance therapy for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP); affects providers submitting medical benefit prior authorizations for Sierra Health and Life members. (Part 1 of 3 — partial document.)

    Policy Summary
    Payersierra health and life
    PolicyTezspire (tezepelumab-ekko) — provider-administered therapy
    Policy CodePolicy 2026D0110K
    Change TypeCriteria added/clarifiedICD-10 codes appendedprior version archived
    Effective DateFeb 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document positive clinical response for reauthorization; initial and reauthorization approvals limited to no more than 12 months.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Replaced language indicating 'the [listed] criteria [must be met] for continuation of therapy' with 'authorization for continued use will be approved for patients currently on Tezspire for the treatment of severe asthma based on the [listed] criteria'.

    Added detailed initial therapy and continuation criteria for Tezspire for CRSwNP including diagnostic requirements, prior therapy trials, concomitant therapy restrictions, prescriber specialty, dosing per FDA labeling, and authorization duration (initial and reauthorization no more than 12 months).

    ICD-10 diagnosis codes J31.0, J32.0, J32.1, J32.2, J32.3, J32.4, J32.8, J32.9, J33.0, J33.1, J33.8, and J33.9 were added to the applicable codes list.

    Background, Clinical Evidence, FDA, and References sections were updated to reflect the most current information.

    Previous policy version 2025D0110J was archived.

    12 monthsinitial/reauth duration
    210 mg q4wFDA dosing evaluated
    J2356HCPCS code
    12ICD-10 codes added
    Ages ≥12labeled age

    Coverage Criteria for Tezspire (tezepelumab-ekko)

    inv-01: Severe Asthma — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Severe asthma initial therapy: Diagnosis of severe asthma; and will be used as add-on maintenance therapy; and dosing is in accordance with the United States Food and Drug Administration approved labeling; and initial authorization will be for no more than 12 months; and classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following indicators: poor symptom control (e.g., ACQ > 1.5 or ACT < 20), two or more systemic corticosteroid bursts (≥3 days each) in the previous 12 months, asthma-related emergency treatment (ER visit, hospitalization, or unscheduled urgent visit), airflow limitation (post-bronchodilator FEV1 < 80% predicted with reduced FEV1/FVC), or dependence on maintenance oral corticosteroids; and used in combination with a maximally-dosed ICS-containing maintenance regimen or appropriate combination controller therapy; and patient is not receiving Tezspire in combination with anti-interleukin 5 therapy (e.g., reslizumab, benralizumab, mepolizumab), anti-IgE therapy (omalizumab), or anti-interleukin 4 therapy (dupilumab) for the same indication; and prescribed by an appropriate specialist where applicable (e.g., pulmonologist or allergist/immunologist).

    Indicators include ACQ > 1.5 or ACT < 20; two or more systemic steroid bursts in prior 12 months; asthma-related emergency care; airflow limitation; maintenance oral corticosteroid dependence.

    inv-02: Severe Asthma — Continuation Therapy — Reauthorization/Continuation of Care — all elements required

    Reauthorization/Continuation of Care — all elements required

    Severe asthma continuation: Documentation of a positive clinical response to Tezspire (e.g., reduction in exacerbation frequency, decreased rescue medication use, increase in percent predicted FEV1 from pretreatment baseline, or reduction in severity/frequency of asthma symptoms); and used in combination with an ICS-containing maintenance medication; and patient is not receiving Tezspire in combination with anti-interleukin 5 therapy (e.g., reslizumab, benralizumab, mepolizumab), anti-IgE therapy (omalizumab), or anti-interleukin 4 therapy (dupilumab) for the same indication; and dosing is in accordance with the United States Food and Drug Administration approved labeling; and reauthorization will be for no more than 12 months.

    inv-03: CRSwNP — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    CRSwNP initial therapy: Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP); and will be used as add-on maintenance therapy; and patient has had an inadequate response to previous therapies; and patient will receive Tezspire as add-on maintenance therapy in combination with intranasal corticosteroids; and patient is not receiving Tezspire in combination with anti-interleukin 5 therapy (e.g., reslizumab, benralizumab, mepolizumab), anti-IgE therapy (omalizumab), or anti-interleukin 4 therapy (dupilumab) for the same indication; and dosing is in accordance with the United States Food and Drug Administration approved labeling; and prescribed by an allergist/immunologist, otolaryngologist, or pulmonologist; and initial authorization will be for no more than 12 months.

    inv-04: CRSwNP — Continuation Therapy — Reauthorization/Continuation of Care — all elements required

    Reauthorization/Continuation of Care — all elements required

    CRSwNP continuation: Documentation of positive clinical response to Tezspire therapy; and patient will continue Tezspire as add-on maintenance therapy in combination with intranasal corticosteroids; and patient is not receiving Tezspire in combination with anti-interleukin 5 therapy (e.g., reslizumab, benralizumab, mepolizumab), anti-IgE therapy (omalizumab), or anti-interleukin 4 therapy (dupilumab) for the same indication; and dosing is in accordance with the United States Food and Drug Administration approved labeling; and reauthorization will be for no more than 12 months.

    inv-05: Initial Therapy (CRSwNP) — Covered for CRSwNP when ALL of the following are met:

    Covered for CRSwNP when ALL of the following are met:

    CRSwNP initial therapy criteria: Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) and will be used as add-on maintenance therapy; patient has had an inadequate response to previous therapies; patient will receive Tezspire in combination with intranasal corticosteroids; dosing in accordance with U.S. FDA labeling; prescribed by an allergist/immunologist, otolaryngologist, or pulmonologist; initial authorization for no more than 12 months; and patient is not receiving Tezspire in combination with anti-IL-5, anti-IgE, or anti-IL-4 therapy for the same indication.
    CRSwNP diagnostic definition: Diagnosis defined by: two or more symptoms for >12 weeks (nasal mucopurulent discharge; nasal obstruction/blockage/congestion; facial pain/pressure/fullness; reduction or loss of sense of smell) AND one of the following endoscopy/CT findings: purulent mucus or edema in the middle meatus or ethmoid regions; polyps in the nasal cavity or middle meatus; or radiographic mucosal thickening/partial or complete opacification; AND presence of bilateral nasal polyposis or prior bilateral nasal polyp surgery.
    Prior treatments or history required: Patient has required prior sinus surgery, or has required systemic corticosteroids for CRSwNP in the previous 2 years, or has been unable to obtain symptom relief after trial of two of the following classes: nasal saline irrigations; intranasal corticosteroids; antileukotriene agents.

    inv-06: Continuation Therapy (CRSwNP) — Continuation/reauthorization covered when ALL of the following are met:

    Continuation/reauthorization covered when ALL of the following are met:

    CRSwNP continuation criteria: Documentation of positive clinical response to Tezspire; patient will continue Tezspire as add-on maintenance therapy in combination with intranasal corticosteroids; patient is not receiving Tezspire in combination with anti-IL-5, anti-IgE, or anti-IL-4 therapy for the same indication; dosing is in accordance with U.S. FDA labeling; reauthorization will be for no more than 12 months.

    inv-07: Clinical Evidence (Severe Asthma) — Severe asthma coverage context (informational clinical evidence supporting use):

    Severe asthma coverage context (informational clinical evidence supporting use):

    Severe asthma evidence summary: Tezepelumab is indicated as add-on maintenance therapy for severe asthma (ages ≥12); PATHWAY and NAVIGATOR trials demonstrated significant reductions in annualized asthma exacerbation rates versus placebo, and NAVIGATOR showed benefit regardless of baseline blood eosinophils or FeNO.

    Not an authorization algorithm but provides supportive evidence for coverage decisions.

    Concurrent administration of Tezspire (tezepelumab-ekko) with other biologic therapies for the same clinical indication is not permitted. Specifically, patients must not receive Tezspire in combination with anti‑interleukin‑5 therapies (for example, reslizumab, benralizumab, mepolizumab), anti‑IgE therapy (omalizumab), or anti‑interleukin‑4 therapy (dupilumab) when treating the same condition. This restriction applies to both initial therapy and continuation/reauthorization determinations.

    The policy explicitly requires that Tezspire not be used in combination with anti‑IL‑5, anti‑IgE, or anti‑IL‑4 therapies for the same indication. Requests for coverage that propose concurrent use for the same diagnosis (e.g., severe asthma or CRSwNP) should be denied or considered not consistent with the coverage criteria unless clear documentation demonstrates distinct, non‑overlapping indications supported by the member's benefit plan.

    This policy is informational and reflects UnitedHealthcare standard benefit plan interpretation; providers must verify the member’s specific benefit plan and any applicable federal or state mandates. In the event of conflict, the member‑specific benefit plan document governs, and plan‑level exclusions or limits may apply beyond the criteria described here.

    Tezspire is indicated as add‑on maintenance therapy for patients with uncontrolled or inadequately controlled asthma. The policy states Tezspire is not indicated when asthma is controlled (i.e., the patient does not meet the documented uncontrolled criteria such as ACQ > 1.5 or ACT < 20, ≥2 systemic steroid bursts in the prior 12 months, asthma‑related emergency treatment, airflow limitation, or maintenance oral corticosteroid dependence). For continuation/reauthorization, the patient must show documentation of a positive clinical response and continue concomitant ICS‑containing maintenance therapy per the coverage requirements.

    Initial therapy requests for CRSwNP or severe asthma that do not meet the documented diagnostic criteria, prior therapy requirements, or required concomitant controller therapy should be considered not meeting medical necessity. For CRSwNP, initial authorization requires documented diagnostic evidence (symptoms >12 weeks, endoscopy or CT findings, bilateral nasal polyposis or prior bilateral polypectomy) and history of prior sinus surgery or systemic corticosteroid use within 2 years or failed trials of two specified classes; absence of these elements may justify denial of initial therapy requests.

    No additional not‑medically‑necessary conditions are explicitly stated in this excerpt beyond those implied by failure to meet the stated criteria. Operationally, requests are considered not medically necessary when they lack required diagnostic documentation, prior therapy trials, concomitant intranasal or inhaled corticosteroid therapy, or if they propose concurrent use with the excluded biologics. Always confirm member‑specific plan language and mandates before making a final medical necessity determination.

    Coding and Diagnosis Codes

    Procedure/HCPCSHCPCS
    J2356Injection, tezepelumab-ekko, 1 mg.
    Diagnosis/ICD-10ICD-10
    J31.0Chronic rhinitis.
    J32.0Chronic maxillary sinusitis.
    J32.1Chronic frontal sinusitis.
    J32.2Chronic ethmoidal sinusitis.
    J32.3Chronic sphenoidal sinusitis.
    J32.4Chronic pansinusitis.
    J32.8Other chronic sinusitis.
    J32.9Chronic sinusitis, unspecified.
    J33.0Polyp of nasal cavity.
    J33.1Polypoid sinus degeneration.
    1–10 of 16
    1/2
    Applicable ICD-10 Diagnosis Codes (added)ICD-10
    J31.0
    J32.0
    J32.1
    J32.2
    J32.3
    J32.4
    J32.8
    J32.9
    J33.0
    J33.1
    1–10 of 12
    1/2
    Added ICD-10 Diagnosis CodesICD-10
    J31.0Chronic rhinitis
    J32.0Chronic maxillary sinusitis
    J32.1Chronic frontal sinusitis
    J32.2Chronic ethmoidal sinusitis
    J32.3Chronic sphenoidal sinusitis
    J32.4Chronic pansinusitis
    J32.8Other chronic sinusitis
    J32.9Chronic sinusitis, unspecified
    J33.0Polyp of nasal cavity
    J33.1Polypoid sinus degeneration
    1–10 of 12
    1/2
    ACQ/ACT symptom control thresholds
    ACQ/ACT symptomatic thresholdACQ score consistently greater than 1.5 OR ACT score consistently less than 20
    Other indicators (also qualify as uncontrolled)Two or more systemic corticosteroid bursts (≥3 days each) in prior 12 months
    Additional qualifying eventsAsthma-related emergency treatment (ER visit, hospitalization, or unscheduled urgent visit requiring nebulizer/other urgent treatment)
    Physiologic evidenceAirflow limitation: post-bronchodilator FEV1 < 80% predicted with reduced FEV1/FVC
    OCS dependenceCurrent dependence on maintenance oral corticosteroids for asthma treatment

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Initial approvals will be limited to no more than 12 months; reauthorization/continuation approvals will also be for no more than 12 months. Providers must verify member-specific benefits and any applicable federal or state mandates before relying on this policy; the member-specific benefit plan document governs in the event of a conflict.

    • Initial authorization: ≤ 12 months
    • Reauthorization/continuation: ≤ 12 months
    • Check member-specific benefit plan and applicable mandates before submitting
    Documentation Required

    Required Documentation for CRSwNP Initial Authorization

    For CRSwNP initial authorization, documentation must show the diagnosis and objective findings consistent with chronic rhinosinusitis with nasal polyps and prior therapy attempts. Required documentation includes symptom duration >12 weeks with two or more key symptoms and nasal endoscopy and/or sinus CT findings (e.g., purulent mucus or edema in the middle meatus/ethmoid regions, polyps in the nasal cavity or middle meatus, or mucosal thickening/partial or complete opacification on imaging).

    Background and Clinical Context

    Asthma is a chronic inflammatory airway disease; an estimated portion of patients (commonly cited as 5–10%) have severe disease requiring specialty biologic therapy. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition of the nasal passages and paranasal sinuses characterized by polyps and symptoms lasting more than 12 weeks. Standard care for CRSwNP includes intranasal corticosteroids, systemic corticosteroids, and sinus surgery when indicated. Tezspire is a human monoclonal antibody that binds thymic stromal lymphopoietin (TSLP), reducing downstream airway and mucosal inflammation and providing an add‑on maintenance option across asthma phenotypes and for CRSwNP when patients meet the policy criteria.

    Key Definitions

    Eosinophilic asthma
    DefinitionAsthma phenotype characterized by elevated blood and sputum eosinophils and often elevated FeNO
    Clinical relevanceIdentifies patients with type 2 eosinophilic inflammation targeted by downstream biologics (e.g., anti-IL-5)
    Phenotype overlapApproximately one-half of patients may have overlapping or changing phenotypes
    Implication for tezepelumabTezepelumab acts upstream (TSLP) and may be effective irrespective of eosinophilic phenotype
    Tezepelumab mechanism
    Mechanism of actionHuman monoclonal antibody that binds thymic stromal lymphopoietin (TSLP)
    Policy Summary
    Payersierra health and life
    PolicyTezspire (tezepelumab-ekko) — provider-administered therapy
    Policy CodePolicy 2026D0110K
    Change TypeCriteria added/clarifiedICD-10 codes appendedprior version archived
    Effective DateFeb 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document positive clinical response for reauthorization; initial and reauthorization approvals limited to no more than 12 months.
    SourceLink
    On This Page
    Coverage Criteria for Tezspire (tezepelumab-ekko)Coding and Diagnosis CodesProvider Requirements, Prior Authorization, and DocumentationBackground and Clinical ContextKey Definitions
    • Two or more symptoms >12 weeks: nasal mucopurulent discharge; nasal obstruction/blockage/congestion; facial pain/pressure/fullness; reduction or loss of smell
    • Objective finding: nasal endoscopy and/or sinus CT demonstrating purulence/edema, polyps, or mucosal thickening/opacification
    Step Therapy

    Prior Therapy Requirements for CRSwNP

    Prior therapy requirements for CRSwNP must be documented. Patient must have had an inadequate response to previous therapies, which may include prior sinus surgery or systemic corticosteroids in the prior 2 years, or failure to obtain symptom relief after trial of two classes of agents.

    • Prior sinus surgery OR systemic corticosteroids (e.g., prednisone, methylprednisolone) for CRSwNP in past 2 years
    • OR inadequate response after trial of two classes among: nasal saline irrigations; intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone); antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)
    Documentation Required

    Required Clinical Response Documentation for Reauthorization

    For reauthorization/continuation (both severe asthma and CRSwNP), documentation of positive clinical response is required. Examples of acceptable evidence include reduced exacerbation frequency, decreased rescue medication use, increased percent predicted FEV1 from pretreatment baseline, or reduced severity/frequency of disease-related symptoms.

    • Reduction in frequency of exacerbations
    • Decreased utilization of rescue medications
    • Increase in % predicted FEV1 from pretreatment baseline
    • Reduction in severity or frequency of disease-related symptoms (e.g., wheezing, shortness of breath, coughing)
    Denial Risk

    Triggers and Potential Denial Reasons

    Requests may be denied if required diagnostic criteria or documentation are not provided, if the drug is not being used as add-on maintenance therapy, or if required prior therapy requirements for CRSwNP are not met. Requests may also be denied when Tezspire is prescribed concurrently with disallowed biologic therapies for the same indication.

    • Denial triggers: missing required diagnosis or objective findings for CRSwNP
    • Denial triggers: therapy not documented as add-on maintenance
    • Denial triggers: prior therapy requirements for CRSwNP not met
    • Denial triggers: concurrent use with anti-IL-5, anti-IgE, or anti-IL-4 therapies for the same indication (e.g., reslizumab, benralizumab, mepolizumab, omalizumab, dupilumab)
    Note

    Verify Member-Specific Plan and Use of Third-Party Tools

    Before submitting an authorization request, providers must check the member-specific benefit plan document and any applicable federal or state mandates. Failure to reference the member-specific plan may result in coverage issues. UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits.

    • Member-specific benefit plan governs in event of conflict with this policy
    • Verify member-specific benefits and mandates prior to relying on this policy
    • UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administration
    Pharmacologic effect
    Blocks TSLP interaction with its receptor, reducing downstream airway and mucosal inflammatory markers (eg, blood eosinophils, IgE, FeNO, IL-5, IL-13)
    Position in cascadeActs at the top of the inflammatory cascade (upstream), distinguishing it from biologics that target downstream pathways
    Clinical implicationUpstream activity makes tezepelumab suitable across a broad spectrum of severe asthma phenotypes
    Definition of severe asthma
    Core definitionSevere asthma is asthma that remains uncontrolled despite adherence with maximal optimized high-dose ICS-LABA treatment and management of contributory factors, or that worsens when high-dose treatment is decreased
    Exclusion noteAsthma is not classified as severe if it markedly improves after addressing contributory factors (eg, inhaler technique, adherence)
    Recommended therapy contextGINA recommends add-on biologic therapy for adults, adolescents, and children with uncontrolled severe asthma despite optimized maximal therapy
    Definition of uncontrolled asthma
    Clinical definitionUncontrolled asthma: poor symptom control and/or frequent exacerbations (eg, frequent symptoms, activity limitation, night waking) and/or frequent exacerbations (≥2/year requiring oral corticosteroids) or serious exacerbation (≥1/year requiring hospitalization)
    Symptom indicatorsFrequent reliever use, activity limitation, or night waking due to asthma
    Exacerbation thresholds≥2 exacerbations/year requiring systemic corticosteroids OR ≥1 serious exacerbation/year requiring hospitalization
    Relation to severe asthmaUncontrolled asthma is the clinical state that may qualify a patient for consideration of add-on biologic therapy when optimised therapy has failed